Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics

Marco Caminati; Andrea Vianello; Margherita Andretta; Anna Michela Menti; Silvia Tognella; Luca Degli Esposti; Claudio Micheletto; Chiara Bovo; Gianenrico Senna

doi:10.1183/23120541.00017-2020

Low adherence to inhaled corticosteroids/long-acting β₂-agonists and biologic treatment in severe asthmatics

ERJ Open Res. 2020 Apr 27;6(2):00017-2020. doi: 10.1183/23120541.00017-2020. eCollection 2020 Apr.

Authors

Marco Caminati^{1

2}, Andrea Vianello³, Margherita Andretta⁴, Anna Michela Menti⁴, Silvia Tognella⁵, Luca Degli Esposti⁶, Claudio Micheletto⁷, Chiara Bovo⁸, Gianenrico Senna¹

Affiliations

¹ Asthma Center and Allergy Unit, Verona University and General Hospital, Verona, Italy.
² Dept of Medicine, University of Verona, Verona, Italy.
³ Respiratory Pathophysiology Division, University-City Hospital of Padua, Padua, Italy.
⁴ Health Technology Assessment Unit, Azienda Zero, Padua, Italy.
⁵ Respiratory Unit, Orlandi General Hospital, Verona, Italy.
⁶ CliCon S.r.l. Health, Economics and Outcomes Research, Ravenna, Italy.
⁷ Cardio-Thoracic Dept, Respiratory Unit, Integrated University Hospital, Verona, Italy.
⁸ Medical Direction, University Hospital of Verona, Verona, Italy.

Abstract

Less than half of severe asthmatic patients show a >80% adherence rate to inhaled treatment just before and during biologic therapy. This has implications in biologic treatment sustainability and disease prevalence estimation. http://bit.ly/3cRTJB0.